MaaT Pharma Raises €9.1 Million in Capital Increase
MaaT Pharma, specializing in the development of microbiotic therapies, has announced the successful completion of its capital increase amounting to €9.1 million, according to the press release.
Details of the Capital Increase
MaaT Pharma initiated a capital increase that resulted in raising €9.1 million, including a private offering of 2,168,072 new ordinary shares to qualified investors and a public offering of 447,478 shares through the PrimaryBid platform, according to the press release. The share price was set at €3.48 per share, the company specifies. The net proceeds are estimated at approximately €8.7 million.
Purpose of the Raised Funds
According to MaaT Pharma, the funds from the capital increase will be used to finance the development of Microbiome Ecosystem Therapies™, particularly the preparation of Xervyteg® for its commercialization in Europe scheduled for the second half of 2026. This includes associated regulatory activities and the continuation of the MaaT033 clinical trial in Europe. Discussions with the FDA for a pivotal study in the United States, planned to start in early 2026, are also on the agenda. Additionally, these funds will cover working capital needs and general corporate expenses.
Financial Position and Future Plans
MaaT Pharma reports that cash and cash equivalents as of September 30, 2025, amounted to €22.4 million, including an initial payment of €10.5 million from its commercial partner. The company believes that its financial discipline will support its development programs until the end of February 2026. The capital increase also meets the conditions for drawing a second tranche of financing from the European Investment Bank, which would extend the cash horizon until August 2026. MaaT Pharma is also exploring additional financing options to further extend its cash runway.
